# | Title | Journal | Year | Citations |
---|
1 | Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer | New England Journal of Medicine | 2015 | 5,183 |
2 | Guidelines for the use and interpretation of assays for monitoring autophagy | Autophagy | 2012 | 3,122 |
3 | Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial | Lancet, The | 2017 | 1,749 |
4 | Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer | Nature Medicine | 2018 | 1,071 |
5 | Phosphorylation of p62 Activates the Keap1-Nrf2 Pathway during Selective Autophagy | Molecular Cell | 2013 | 880 |
6 | Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer | Nature Communications | 2017 | 743 |
7 | Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine | Nature Medicine | 2013 | 661 |
8 | Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project | Blood | 2009 | 656 |
9 | Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis | Proceedings of the National Academy of Sciences of the United States of America | 2012 | 654 |
10 | Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer | Nature Medicine | 2013 | 634 |
11 | Loss of Autophagy Diminishes Pancreatic β Cell Mass and Function with Resultant Hyperglycemia | Cell Metabolism | 2008 | 586 |
12 | Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma | Journal of Hepatology | 2022 | 568 |
13 | Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma | Nature Communications | 2020 | 565 |
14 | Extranodal Natural Killer T-Cell Lymphoma, Nasal-Type: A Prognostic Model From a Retrospective Multicenter Study | Journal of Clinical Oncology | 2006 | 560 |
15 | Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells | Journal of Cell Biology | 2011 | 520 |
16 | Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis | Gut | 2013 | 497 |
17 | Clinical Significance of Differentiation of Mycobacterium massiliense from Mycobacterium abscessus | American Journal of Respiratory and Critical Care Medicine | 2011 | 464 |
18 | Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study | Lancet Oncology, The | 2020 | 441 |
19 | Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention | JAMA - Journal of the American Medical Association | 2019 | 424 |
20 | Gastric adenocarcinoma | Nature Reviews Disease Primers | 2017 | 409 |
21 | PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase | Blood | 2017 | 399 |
22 | Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300 | Annals of Oncology | 2018 | 387 |
23 | Progression of Monoclonal Gammopathy with Undetermined Significance to Multiple Myeloma Diagnosed by Kidney Biopsy: A Case Report | Case Reports in Nephrology and Dialysis | 2015 | 375 |
24 | Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma | Gastroenterology | 2015 | 371 |
25 | SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group | Blood | 2012 | 361 |
26 | Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study | Lancet Oncology, The | 2011 | 356 |
27 | Serum exosomal microRNAs as novel biomarkers for hepatocellular carcinoma | Experimental and Molecular Medicine | 2015 | 353 |
28 | Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project | Clinical Cancer Research | 2017 | 342 |
29 | Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial | Lancet Oncology, The | 2014 | 336 |
30 | Decreased Number and Impaired Angiogenic Function of Endothelial Progenitor Cells in Patients With Chronic Renal Failure | Arteriosclerosis, Thrombosis, and Vascular Biology | 2004 | 317 |
31 | Phase II Trial of Concurrent Radiation and Weekly Cisplatin Followed by VIPD Chemotherapy in Newly Diagnosed, Stage IE to IIE, Nasal, Extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma Study | Journal of Clinical Oncology | 2009 | 312 |
32 | Preoperative gadoxetic acid–enhanced MRI for predicting microvascular invasion in patients with single hepatocellular carcinoma | Journal of Hepatology | 2017 | 299 |
33 | Antibiotic Treatment of Mycobacterium abscessus Lung Disease | American Journal of Respiratory and Critical Care Medicine | 2009 | 293 |
34 | TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer | Annals of Oncology | 2020 | 289 |
35 | What is asthma−COPD overlap syndrome? Towards a consensus definition from a round table discussion | European Respiratory Journal | 2016 | 287 |
36 | Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer | Annals of Oncology | 2007 | 285 |
37 | The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma | Blood | 2007 | 283 |
38 | Glycemic Variability: How Do We Measure It and Why Is It Important? | Diabetes and Metabolism Journal | 2015 | 276 |
39 | A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC) | Annals of Oncology | 2015 | 275 |
40 | Challenges of Convalescent Plasma Infusion Therapy in Middle East Respiratory Coronavirus Infection: A Single Centre Experience | Antiviral Therapy | 2018 | 275 |
41 | Comparison of Guaiac-Based and Quantitative Immunochemical Fecal Occult Blood Testing in a Population at Average Risk Undergoing Colorectal Cancer Screening | American Journal of Gastroenterology | 2010 | 268 |
42 | Update on pulmonary disease due to non-tuberculous mycobacteria | International Journal of Infectious Diseases | 2016 | 267 |
43 | DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load | Nature Communications | 2019 | 263 |
44 | 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial | Lancet, The | 2018 | 261 |
45 | The emerging role of autophagy in the pathophysiology of diabetes mellitus | Autophagy | 2011 | 252 |
46 | Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma | Cancer Discovery | 2018 | 248 |
47 | Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype | Nature Communications | 2018 | 245 |
48 | Trophic Molecules Derived From Human Mesenchymal Stem Cells Enhance Survival, Function, and Angiogenesis of Isolated Islets After Transplantation | Transplantation | 2010 | 241 |
49 | Saturated fatty acids inhibit induction of insulin gene transcription by JNK-mediated phosphorylation of insulin-receptor substrates | Proceedings of the National Academy of Sciences of the United States of America | 2006 | 240 |
50 | Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4) | Annals of Oncology | 2019 | 230 |